Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Crossref DOI link: https://doi.org/10.1186/s13045-015-0194-5
Published Online: 2015-08-13
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lu, Janice
Funding for this research was provided by:
The Research Foundation at UCLA (ID0E5OAE534)